Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16125248 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL15253319 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL15253076 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL16125250 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL15045873 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL15253320 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL15253074 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL16125249 | 0.97 | NR1I2 (0.41) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL15253093 | 0.97 | NR1I2 (0.41) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL15253094 | 0.97 | NR1I2 (0.41) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013090420-A2 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ALDH1A1 1235/4885CYP3A4 2263/4885ALOX15 89/4885 |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ALDH1A1 1235/4885CYP3A4 2263/4885ALOX15 89/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ALDH1A1 1235/4885CYP3A4 2263/4885ALOX15 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.